Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 6, keine Gesamtzahl für „Combination“
Suchtreffer
Begriffe & Kennungen
Braftovi · 4.8 · When encorafenib was used at a dose of 300 mg once daily in combination with binimetinib 45 mg twice daily (Co
Eintrag öffnenBrimonidintartrat-Timololmaleat-Wirkstoffkombination
Eintrag öffnenBrintellix · 4.5 · Reversible, non-selective MAOI (linezolid) The combination of vortioxetine with a weak reversible and non-sele
Eintrag öffnenBrintellix · 4.5 · Reversible, non-selective MAOI (linezolid) The combination of vortioxetine with a weak reversible and non-sele
Eintrag öffnenBrintellix · 4.5 · Reversible, selective MAO-A inhibitor (moclobemide) The combination of vortioxetine with a reversible and sele
Eintrag öffnenBrintellix · 4.5 · Reversible, selective MAO-A inhibitor (moclobemide) The combination of vortioxetine with a reversible and sele
Eintrag öffnenBrukinsa · 4.8 · 34 Zanubrutinib in combination with obinutuzumab The most commonly occurring adverse reactions (≥20%) of zanub
Eintrag öffnenBrukinsa · 4.8 · 36 Table 4: Adverse reactions of zanubrutinib in combination with obinutuzumab reported in clinical study BGB-
Eintrag öffnenBrukinsa · 4.8 · 8 The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib in combination with obinutuzumab w
Eintrag öffnenBrukinsa · 4.8 · Adverse reactions in patients treated with BRUKINSA as monotherapy or in combination with obinutuzumab for B-c
Eintrag öffnenBrukinsa · 4.8 · Adverse reactions in patients treated with BRUKINSA as monotherapy or in combination with obinutuzumab for B-c
Eintrag öffnenBrukinsa · 4.8 · Of the 143 patients treated with BRUKINSA in combination with obinutuzumab, 42.0% were 65 years of age or olde
Eintrag öffnenBrukinsa · 4.8 · Of the 143 patients treated with BRUKINSA in combination with obinutuzumab, 42.0% were 65 years of age or olde
Eintrag öffnenBrukinsa · 4.8 · Of the 143 patients treated with zanubrutinib in combination with obinutuzumab, 4.9% of patients discontinued
Eintrag öffnenBrukinsa · 4.8 · Of the 143 patients treated with zanubrutinib in combination with obinutuzumab, 4.9% of patients discontinued
Eintrag öffnenBrukinsa · 4.8 · Table 4: Adverse reactions of zanubrutinib in combination with obinutuzumab reported in clinical study BGB-311
Eintrag öffnenBrukinsa · 4.8 · The most common Grade 3 or higher adverse reactions (>3%) of zanubrutinib in combination with obinutuzumab wer
Eintrag öffnenBrukinsa · 4.8 · The safety profile of zanubrutinib in combination with obinutuzumab is based on ROSEWOOD study data from 143 p
Eintrag öffnenBrukinsa · 4.8 · The safety profile of zanubrutinib in combination with obinutuzumab is based on ROSEWOOD study data from 143 p
Eintrag öffnenBrukinsa · 4.8 · Zanubrutinib in combination with obinutuzumab The most commonly occurring adverse reactions (≥20%) of zanubrut
Eintrag öffnen